Amneal Pharma Files 8-K on Operations & Financial Condition

TL;DR

**Amneal just dropped an 8-K on its financials, get ready for potential stock movement.**

AI Summary

Amneal Pharmaceuticals, Inc. filed an 8-K on January 10, 2024, to report on its 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure'. This filing indicates that the company is providing an update on its financial performance, likely ahead of a formal earnings release, to ensure fair and broad dissemination of material non-public information. For investors, this matters because it signals that important financial details about Amneal (AMRX) are being shared, which could influence stock price movements as the market digests the information.

Why It Matters

This filing indicates Amneal is proactively disclosing financial updates, which can provide early insights into its performance and potentially impact investor sentiment and stock valuation.

Risk Assessment

Risk Level: medium — The filing itself is procedural, but the undisclosed financial information it refers to could contain significant positive or negative news, creating uncertainty.

Analyst Insight

A smart investor would monitor Amneal's news channels and future filings closely for the specific financial details mentioned in this 8-K, as they will provide the actual substance behind this procedural disclosure.

Key Players & Entities

• Amneal Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
• January 10, 2024 (date) — date of earliest event reported and filing date
• 001-38485 (string) — Commission File Number for Amneal Pharmaceuticals, Inc.
• AMRX (string) — trading symbol for Amneal Pharmaceuticals, Inc. Class A Common Stock
• The Nasdaq Stock Market LLC (string) — exchange where Amneal's Class A Common Stock is registered

FAQ

Key Financial Figures

• $0.01 — stered Class A Common Stock, par value $0.01 per share AMRX The Nasdaq Stock Market
• $2.37 billion — ird quarter 2023 results: Net revenue $2.37 billion - $2.42 billion Adjusted EBITDA (1) $
• $2.42 billion — results: Net revenue $2.37 billion - $2.42 billion Adjusted EBITDA (1) $540 million - $5
• $540 million — n - $2.42 billion Adjusted EBITDA (1) $540 million - $550 million Adjusted diluted EPS (2
• $550 million — on Adjusted EBITDA (1) $540 million - $550 million Adjusted diluted EPS (2) $0.51 - $0.5
• $0.51 — $550 million Adjusted diluted EPS (2) $0.51 - $0.58 Operating cash flow (3) $250
• $0.58 — lion Adjusted diluted EPS (2) $0.51 - $0.58 Operating cash flow (3) $250 million
• $250 million — $0.51 - $0.58 Operating cash flow (3) $250 million - $280 million Capital expenditures $5
• $280 million — Operating cash flow (3) $250 million - $280 million Capital expenditures $50 million - $60
• $50 million — on - $280 million Capital expenditures $50 million - $60 million Weighted average diluted
• $60 million — ion Capital expenditures $50 million - $60 million Weighted average diluted shares outsta

Filing Documents

• amrx-20240110.htm (8-K) — 38KB
• 0001723128-24-000003.txt ( ) — 165KB
• amrx-20240110.xsd (EX-101.SCH) — 2KB
• amrx-20240110_lab.xml (EX-101.LAB) — 24KB
• amrx-20240110_pre.xml (EX-101.PRE) — 12KB
• amrx-20240110_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. In connection with a presentation to be made at an investor conference on January 10, 2024, Amneal Pharmaceuticals, Inc., a Delaware corporation (the "Company"), reaffirmed guidance with respect to the year ended December 31, 2023, which was previously announced on November 7, 2023 in connection with announcing the Company's third quarter 2023 results: Net revenue $2.37 billion - $2.42 billion Adjusted EBITDA (1) $540 million - $550 million Adjusted diluted EPS (2) $0.51 - $0.58 Operating cash flow (3) $250 million - $280 million Capital expenditures $50 million - $60 million Weighted average diluted shares outstanding (4) Approximately 310 million (1) Includes 100% of Adjusted EBITDA from the AvKARE acquisition. (2) Accounts for 35% non-controlling interest in AvKARE. (3) Does not contemplate one time and non-recurring items such as legal settlements and other discrete items. (4) Assumes (i) the weighted average diluted shares outstanding of class A common stock and (ii) as if all class B common stock was converted to class A common stock as of January 1, 2023. The Company's 2023 estimates are based on management's current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits,

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure The disclosure in Item 2.02 hereof is incorporated by reference into this item 7.01.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 10, 2024 AMNEAL PHARMACEUTICALS, INC. By: /s/ Anastasios Konidaris Name: Anastasios Konidaris Title: Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)

View Full Filing

View this 8-K filing on SEC EDGAR